FTH logo

FTH Faeth Therapeutics, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$10.03
-0.62 (-5.82%)

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]

Market Cap: $258.56Mwww.faeththerapeutics.com

Price

No data yet.

Social Signal Score

53
5d
—
30d
50
1 mentions
—
60d
50
2 mentions
—
90d
60
4 mentions
—
news: 4

Analyst Ratings

6 analysts
Buyconsensus
Strong Buy 0Buy 6Hold 0Sell 0Strong Sell 0
Avg price target$58.5+483.3%
Low $50Median $58High $70
Current Consensus

Revenue

$0.00
$-4.85M$-3.23M$-1.62M$0.00
Dec 2019Sep 2026

Analyst Estimates

FY2025
$-18.17
$-18.17–$-18.17
3 analysts
FY2026
$-15.25
$-16.89–$-13.57
6 analysts
FY2027
$-3.55
$-5.34–$-2.84
7 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Anand Parikh
Sector
Healthcare
Industry
Biotechnology
Employees
29
Beta
-0.30
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
4.35
www.faeththerapeutics.com